

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human VEGF based on Bevacizumab therapeutic antibody.
<b>Source</b>	Recombinant Monoclonal Human IgG <sub>1</sub> Clone # Hu101
<b>Purification</b>	Protein A or G purified from cell culture supernatant
<b>Immunogen</b>	Human VEGF-A
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

**Neutralization** Measured by its ability to neutralize VEGF<sub>165</sub>-induced proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND<sub>50</sub>) is typically 10-80 ng/mL in the presence of 10 ng/mL Recombinant Human VEGF<sub>165</sub>.

## DATA



## PREPARATION AND STORAGE

- Shipping** The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.  
\*Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
- Stability & Storage** **Use a manual defrost freezer and avoid repeated freeze-thaw cycles.**
- 12 months from date of receipt, -20 to -70 °C, as supplied.
  - 1 month, 2 to 8 °C under sterile conditions after opening.
  - 6 months, -20 to -70 °C under sterile conditions after opening.

## BACKGROUND

Bevacizumab is a biosimilar directed against VEGF. This product can be used as the standard in pharmacokinetic (PK) assays.